Treatment of Candida glabrata in Urine Without Catheter
For most patients with Candida glabrata isolated from urine without a catheter, treatment with antifungal agents is NOT recommended unless they belong to high-risk groups (neutropenic patients, very low-birth-weight infants <1500g, or those undergoing urologic procedures). 1
Risk Stratification and Treatment Algorithm
Step 1: Determine if Treatment is Necessary
The critical first decision is whether antifungal therapy is indicated at all. The IDSA guidelines strongly recommend against treating candiduria in most patients, as this typically represents colonization rather than true infection 1.
Treat only if the patient has:
- Neutropenia
- Very low birth weight (<1500g)
- Planned urologic manipulation/procedures
- Symptomatic cystitis with pyuria
- Symptomatic pyelonephritis
- Evidence of urinary tract obstruction
Step 2: Obtain Susceptibility Testing
Before initiating therapy, obtain antifungal susceptibility testing because C. glabrata has variable fluconazole resistance patterns. This is crucial as C. glabrata is intrinsically less susceptible to azoles compared to C. albicans 1.
Step 3: Treatment Based on Location and Susceptibility
For Symptomatic Cystitis (Lower UTI):
If fluconazole-susceptible:
- Oral fluconazole 200 mg (3 mg/kg) daily for 2 weeks 1
If fluconazole-resistant C. glabrata:
- Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days 1
- OR oral flucytosine 25 mg/kg four times daily for 7–10 days 1
- Amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) may be considered as adjunctive therapy 1
For Symptomatic Pyelonephritis (Upper UTI):
If fluconazole-susceptible:
- Oral fluconazole 200–400 mg (3–6 mg/kg) daily for 2 weeks 1
If fluconazole-resistant C. glabrata:
- Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days with or without oral flucytosine 25 mg/kg four times daily 1
- Monotherapy with oral flucytosine 25 mg/kg four times daily for 2 weeks could be considered (weaker recommendation) 1
Eliminate urinary tract obstruction if present (nephrostomy tubes, stents should be removed or replaced if feasible) 1
For Patients Undergoing Urologic Procedures:
Prophylactic treatment before and after procedure:
- Oral fluconazole 400 mg (6 mg/kg) daily for several days before and after 1
- OR amphotericin B deoxycholate 0.3–0.6 mg/kg daily 1
Important Caveats and Pitfalls
Echinocandins Are NOT Recommended for Urinary Tract Infections
Despite their excellent activity against C. glabrata systemically, echinocandins (caspofungin, micafungin, anidulafungin) achieve inadequate urine concentrations and should not be used for isolated urinary candidiasis 2. The case reports describing micafungin success 3, 4 involved bacteremia/pyelonephritis with systemic infection, not isolated candiduria—these patients required systemic therapy for bloodstream infection, not just urinary tract treatment.
Fluconazole Achieves Excellent Urine Concentrations
Fluconazole is the preferred agent when susceptible because it achieves high urinary concentrations with oral administration 2, 5. This makes it ideal for outpatient management.
C. glabrata Resistance Patterns
C. glabrata exhibits intrinsic reduced susceptibility to fluconazole and may develop resistance during therapy. Always check susceptibility testing rather than assuming susceptibility 1, 6. Regional resistance patterns vary significantly 6.
Asymptomatic Candiduria Does Not Require Treatment
Approximately 50% of asymptomatic candiduria resolves spontaneously after removing predisposing factors 2, 7. Do not treat asymptomatic candiduria in immunocompetent patients without catheters unless they fall into high-risk categories 1.
SGLT2 Inhibitor Consideration
Patients on SGLT2 inhibitors may have increased risk of Candida urinary colonization and potential infection 3. Maintain higher clinical suspicion in symptomatic patients on these medications, but this does not change treatment algorithms.
Monitor for Treatment Failure
If symptoms persist or cultures remain positive after appropriate therapy, consider:
- Unrecognized urinary tract obstruction
- Inadequate source control
- Development of resistance during therapy
- Disseminated infection requiring systemic candidemia treatment protocols